Click here to view online. Add this email to your safelist.
Calquence data across four trials reinforces cardiovascular safety profile in patients with chronic lymphocytic leukaemia
7 December 2020
A pooled analysis of cardiovascular (CV) safety data from 762 patients treated with Calquence (acalabrutinib) monotherapy for chronic lymphocytic leukaemia (CLL), the most common type of adult leukaemia, across four clinical trials showed a low incidence of cardiac adverse events (AEs) leading to discontinuation. These results were presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition on 7 December 2020.
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
